Generex Biotechnology Corporation – Product Pipeline Review – 2013
Summary
Global Market Direct’s pharmaceuticals report, “Generex Biotechnology Corporation - Product Pipeline Review - 2013” provides data on the Generex Biotechnology Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Generex Biotechnology Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Generex Biotechnology Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Generex Biotechnology Corporation - Product Pipeline Review - 2013” provides data on the Generex Biotechnology Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Generex Biotechnology Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from Generex Biotechnology Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Generex Biotechnology Corporation - Brief Generex Biotechnology Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Generex Biotechnology Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Generex Biotechnology Corporation with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Generex Biotechnology Corporation’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Generex Biotechnology Corporation’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Generex Biotechnology Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Generex Biotechnology Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Generex Biotechnology Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Generex Biotechnology Corporation and identify potential opportunities in those areas.
Generex Biotechnology Corporation Snapshot
Generex Biotechnology Corporation Overview
Key Information
Key Facts
Generex Biotechnology Corporation – Research and Development Overview
Key Therapeutic Areas
Generex Biotechnology Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Generex Biotechnology Corporation – Pipeline Products Glance
Generex Biotechnology Corporation – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Generex Biotechnology Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Generex Biotechnology Corporation – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Generex Biotechnology Corporation – Drug Profiles
AE-37
Product Description
Mechanism of Action
R&D Progress
AE-37 Vaccine + [trastuzumab]
Product Description
Mechanism of Action
R&D Progress
AE-AI Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-H Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-IG Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-M Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-O Vaccine
Product Description
Mechanism of Action
R&D Progress
ardeparin sodium
Product Description
Mechanism of Action
R&D Progress
fentanyl citrate
Product Description
Mechanism of Action
R&D Progress
insulin human
Product Description
Mechanism of Action
R&D Progress
metformin
Product Description
Mechanism of Action
R&D Progress
morphine sulfate
Product Description
Mechanism of Action
R&D Progress
Generex Biotechnology Corporation – Pipeline Analysis
Generex Biotechnology Corporation – Pipeline Products by Therapeutic Class
Generex Biotechnology Corporation – Pipeline Products by Route of Administration
Generex Biotechnology Corporation – Pipeline Products By Mechanism of Action
Generex Biotechnology Corporation – Recent Pipeline Updates
Generex Biotechnology Corporation – Company Statement
Generex Biotechnology Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Generex Biotechnology Corporation, Recent Developments
Generex Biotechnology Corporation- Press Release
Feb 07, 2013: Generex Provides Update On Current Pipeline And Potential Of Antigen Express Technology
Jan 31, 2013: Generex Points To Potential Of Antigen Express Technology Platform Beyond Its AE37 Breast Cancer Vaccine
Jan 30, 2013: Generex Provides An Overview Of Cancer Immunotherapy Product AE37
Jan 23, 2013: Generex Announces Submission Of Oral-lyn Phase III Dossier To Indian Government For Marketing Approval
Dec 13, 2010: Generex Announces Publication Of New Positive Generex Oral-lyn Data In Peer-Reviewed Journal
Dec 06, 2010: Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data At Annual San Antonio Breast Cancer Symposium
Sep 22, 2010: Generex Presents Abstract On Generex Oral-Lyn At EASD Annual Meeting
Sep 14, 2010: Generex Signs Distribution Agreement For Generex Oral-lyn In Chile
Jul 28, 2010: Generex Reports Positive Update On Pivotal Phase III Trial Of Generex Oral-Lyn
Jul 13, 2010: Generex Oncology Granted US Patent For AE37 Peptide Vaccine
May 26, 2010: Generex Biotechnology To Participate In American Society Of Clinical Oncology Annual Meeting In Chic
May 18, 2010: Generex Announces Publication Of Immunotherapeutic Cancer Vaccine Results In Patients With Prostate Cancer
May 10, 2010: Generex Biotechnology Enrolls Over 400 Subjects In Phase III Generex Oral-lyn Trial
Apr 27, 2010: Generex Announces Updated Phase I Results From Novel Immunotherapeutic Vaccine Presented At The Euro
Mar 30, 2010: Generex Announces Expansion Plan For FDA Expanded Access Treatment IND Program For Generex Oral-lyn
Mar 12, 2010: Generex's Oral-Lyn Receives Positive Responses From Independent Physicians And Nurse Practitioners
Jan 19, 2010: Generex Makes Podium Presentation Of Vaccine Technology Platform With Cancer & Influenza Updates At PepTalk 2010
Financial Deals Landscape
Generex Biotechnology Corporation, Deals Summary
Generex Biotechnology Corporation, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Generex Biotech Enters Into Co-Marketing Agreement With Merck
Generex Biotech Enters Into An Angreement With Sanofi-Aventis Deutschland
Generex Biotech Enters Into An Agreement With Pevion Biotech
Generex Biotech Enters Into Collaboration With Mayo Clinic
Generex Biotech Enters Into Distribution Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With University of Rochester
Licensing Agreements
Generex Biotech Enters Into Licensing Agreement With Amarantus BioSciences
Generex Biotech Enters Into Licensing Agreement With PMG For Generex Oral-lyn
Generex Enters Into Licensing And Distribution Agreement With Dongsung Pharma
Generex Biotech Enters Into An Agreement With SciGen
Generex Biotech Enters Into Licensing Agreement With Armenian Development Agency And Canada Armenia Trading House
Equity Offering
Generex Biotech Completes Private Placement Of Units For $0.8 Million
Generex Biotechnology Completes Private Placement Of Units For $0.75 Million
Generex Biotech Completes Private Placement Of Units For $2 Million
Generex Completes Private Placement Of Common Stock For $3 Million
Generex Biotech Completes First Tranche Of Private Placement For $3 Million
Generex Biotech Completes First Tranche Of Private Placement Of $0.94 Million
Generex Completes Registered Direct Offering Of $12 Million
Generex Biotech Completes Registered Direct Offering For $5.65 Million
Generex Biotech Completes Registered Direct Offering Of $10 Million
Generex Biotech Completes Registered Direct Offering For $5 Million
Debt Offering
Generex Completes Private Placement Of 8% Secured Convertible Notes For $21 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Generex Biotechnology Corporation, Key Information
Generex Biotechnology Corporation, Key Facts
Generex Biotechnology Corporation – Pipeline by Indication, 2013
Generex Biotechnology Corporation – Pipeline by Stage of Development, 2013
Generex Biotechnology Corporation – Monotherapy Products in Pipeline, 2013
Generex Biotechnology Corporation – Combination Treatment Modalities in Pipeline, 2013
Generex Biotechnology Corporation – Filed, 2013
Generex Biotechnology Corporation – Phase III, 2013
Generex Biotechnology Corporation – Phase II, 2013
Generex Biotechnology Corporation – Phase I, 2013
Generex Biotechnology Corporation – Pre-Clinical, 2013
Generex Biotechnology Corporation – Pipeline By Therapeutic Class, 2013
Generex Biotechnology Corporation – Pipeline By Route of Administration, 2013
Generex Biotechnology Corporation – Pipeline Products By Mechanism of Action, 2013
Generex Biotechnology Corporation – Recent Pipeline Updates, 2013
Generex Biotechnology Corporation, Subsidiaries
Generex Biotechnology Corporation, Deals Summary
Generex Biotech Enters Into Co-Marketing Agreement With Merck
Generex Biotech Enters Into An Angreement With Sanofi-Aventis Deutschland
Generex Biotech Enters Into An Agreement With Pevion Biotech
Generex Biotech Enters Into Collaboration With Mayo Clinic
Generex Biotech Enters Into Distribution Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With University of Rochester
Generex Biotech Enters Into Licensing Agreement With Amarantus BioSciences
Generex Biotech Enters Into Licensing Agreement With PMG For Generex Oral-lyn
Generex Enters Into Licensing And Distribution Agreement With Dongsung Pharma
Generex Biotech Enters Into An Agreement With SciGen
Generex Biotech Enters Into Licensing Agreement With Armenian Development Agency And Canada Armenia Trading House
Generex Biotech Completes Private Placement Of Units For $0.8 Million
Generex Biotechnology Completes Private Placement Of Units For $0.75 Million
Generex Biotech Completes Private Placement Of Units For $2 Million
Generex Completes Private Placement Of Common Stock For $3 Million
Generex Biotech Completes First Tranche Of Private Placement For $3 Million
Generex Biotech Completes First Tranche Of Private Placement Of $0.94 Million
Generex Completes Registered Direct Offering Of $12 Million
Generex Biotech Completes Registered Direct Offering For $5.65 Million
Generex Biotech Completes Registered Direct Offering Of $10 Million
Generex Biotech Completes Registered Direct Offering For $5 Million
Generex Completes Private Placement Of 8% Secured Convertible Notes For $21 Million
LIST OF FIGURES
Generex Biotechnology Corporation – Pipeline by Indication, 2013
Generex Biotechnology Corporation – Pipeline by Stage of Development, 2013
Generex Biotechnology Corporation – Monotherapy Products in Pipeline, 2013
Generex Biotechnology Corporation – Combination Treatment Modalities in Pipeline, 2013
Generex Biotechnology Corporation – Pipeline By Route of Administration, 2013
Generex Biotechnology Corporation - Pipeline Products By Mechanism of Action, 2013
Generex Biotechnology Corporation Overview
Key Information
Key Facts
Generex Biotechnology Corporation – Research and Development Overview
Key Therapeutic Areas
Generex Biotechnology Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Generex Biotechnology Corporation – Pipeline Products Glance
Generex Biotechnology Corporation – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Generex Biotechnology Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Generex Biotechnology Corporation – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Generex Biotechnology Corporation – Drug Profiles
AE-37
Product Description
Mechanism of Action
R&D Progress
AE-37 Vaccine + [trastuzumab]
Product Description
Mechanism of Action
R&D Progress
AE-AI Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-H Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-IG Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-M Vaccine
Product Description
Mechanism of Action
R&D Progress
AE-O Vaccine
Product Description
Mechanism of Action
R&D Progress
ardeparin sodium
Product Description
Mechanism of Action
R&D Progress
fentanyl citrate
Product Description
Mechanism of Action
R&D Progress
insulin human
Product Description
Mechanism of Action
R&D Progress
metformin
Product Description
Mechanism of Action
R&D Progress
morphine sulfate
Product Description
Mechanism of Action
R&D Progress
Generex Biotechnology Corporation – Pipeline Analysis
Generex Biotechnology Corporation – Pipeline Products by Therapeutic Class
Generex Biotechnology Corporation – Pipeline Products by Route of Administration
Generex Biotechnology Corporation – Pipeline Products By Mechanism of Action
Generex Biotechnology Corporation – Recent Pipeline Updates
Generex Biotechnology Corporation – Company Statement
Generex Biotechnology Corporation – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Generex Biotechnology Corporation, Recent Developments
Generex Biotechnology Corporation- Press Release
Feb 07, 2013: Generex Provides Update On Current Pipeline And Potential Of Antigen Express Technology
Jan 31, 2013: Generex Points To Potential Of Antigen Express Technology Platform Beyond Its AE37 Breast Cancer Vaccine
Jan 30, 2013: Generex Provides An Overview Of Cancer Immunotherapy Product AE37
Jan 23, 2013: Generex Announces Submission Of Oral-lyn Phase III Dossier To Indian Government For Marketing Approval
Dec 13, 2010: Generex Announces Publication Of New Positive Generex Oral-lyn Data In Peer-Reviewed Journal
Dec 06, 2010: Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data At Annual San Antonio Breast Cancer Symposium
Sep 22, 2010: Generex Presents Abstract On Generex Oral-Lyn At EASD Annual Meeting
Sep 14, 2010: Generex Signs Distribution Agreement For Generex Oral-lyn In Chile
Jul 28, 2010: Generex Reports Positive Update On Pivotal Phase III Trial Of Generex Oral-Lyn
Jul 13, 2010: Generex Oncology Granted US Patent For AE37 Peptide Vaccine
May 26, 2010: Generex Biotechnology To Participate In American Society Of Clinical Oncology Annual Meeting In Chic
May 18, 2010: Generex Announces Publication Of Immunotherapeutic Cancer Vaccine Results In Patients With Prostate Cancer
May 10, 2010: Generex Biotechnology Enrolls Over 400 Subjects In Phase III Generex Oral-lyn Trial
Apr 27, 2010: Generex Announces Updated Phase I Results From Novel Immunotherapeutic Vaccine Presented At The Euro
Mar 30, 2010: Generex Announces Expansion Plan For FDA Expanded Access Treatment IND Program For Generex Oral-lyn
Mar 12, 2010: Generex's Oral-Lyn Receives Positive Responses From Independent Physicians And Nurse Practitioners
Jan 19, 2010: Generex Makes Podium Presentation Of Vaccine Technology Platform With Cancer & Influenza Updates At PepTalk 2010
Financial Deals Landscape
Generex Biotechnology Corporation, Deals Summary
Generex Biotechnology Corporation, Pharmaceuticals & Healthcare, Deal Details
Partnerships
Generex Biotech Enters Into Co-Marketing Agreement With Merck
Generex Biotech Enters Into An Angreement With Sanofi-Aventis Deutschland
Generex Biotech Enters Into An Agreement With Pevion Biotech
Generex Biotech Enters Into Collaboration With Mayo Clinic
Generex Biotech Enters Into Distribution Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With University of Rochester
Licensing Agreements
Generex Biotech Enters Into Licensing Agreement With Amarantus BioSciences
Generex Biotech Enters Into Licensing Agreement With PMG For Generex Oral-lyn
Generex Enters Into Licensing And Distribution Agreement With Dongsung Pharma
Generex Biotech Enters Into An Agreement With SciGen
Generex Biotech Enters Into Licensing Agreement With Armenian Development Agency And Canada Armenia Trading House
Equity Offering
Generex Biotech Completes Private Placement Of Units For $0.8 Million
Generex Biotechnology Completes Private Placement Of Units For $0.75 Million
Generex Biotech Completes Private Placement Of Units For $2 Million
Generex Completes Private Placement Of Common Stock For $3 Million
Generex Biotech Completes First Tranche Of Private Placement For $3 Million
Generex Biotech Completes First Tranche Of Private Placement Of $0.94 Million
Generex Completes Registered Direct Offering Of $12 Million
Generex Biotech Completes Registered Direct Offering For $5.65 Million
Generex Biotech Completes Registered Direct Offering Of $10 Million
Generex Biotech Completes Registered Direct Offering For $5 Million
Debt Offering
Generex Completes Private Placement Of 8% Secured Convertible Notes For $21 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Generex Biotechnology Corporation, Key Information
Generex Biotechnology Corporation, Key Facts
Generex Biotechnology Corporation – Pipeline by Indication, 2013
Generex Biotechnology Corporation – Pipeline by Stage of Development, 2013
Generex Biotechnology Corporation – Monotherapy Products in Pipeline, 2013
Generex Biotechnology Corporation – Combination Treatment Modalities in Pipeline, 2013
Generex Biotechnology Corporation – Filed, 2013
Generex Biotechnology Corporation – Phase III, 2013
Generex Biotechnology Corporation – Phase II, 2013
Generex Biotechnology Corporation – Phase I, 2013
Generex Biotechnology Corporation – Pre-Clinical, 2013
Generex Biotechnology Corporation – Pipeline By Therapeutic Class, 2013
Generex Biotechnology Corporation – Pipeline By Route of Administration, 2013
Generex Biotechnology Corporation – Pipeline Products By Mechanism of Action, 2013
Generex Biotechnology Corporation – Recent Pipeline Updates, 2013
Generex Biotechnology Corporation, Subsidiaries
Generex Biotechnology Corporation, Deals Summary
Generex Biotech Enters Into Co-Marketing Agreement With Merck
Generex Biotech Enters Into An Angreement With Sanofi-Aventis Deutschland
Generex Biotech Enters Into An Agreement With Pevion Biotech
Generex Biotech Enters Into Collaboration With Mayo Clinic
Generex Biotech Enters Into Distribution Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With Adcock Ingram
Generex Biotech Enters Into An Agreement With University of Rochester
Generex Biotech Enters Into Licensing Agreement With Amarantus BioSciences
Generex Biotech Enters Into Licensing Agreement With PMG For Generex Oral-lyn
Generex Enters Into Licensing And Distribution Agreement With Dongsung Pharma
Generex Biotech Enters Into An Agreement With SciGen
Generex Biotech Enters Into Licensing Agreement With Armenian Development Agency And Canada Armenia Trading House
Generex Biotech Completes Private Placement Of Units For $0.8 Million
Generex Biotechnology Completes Private Placement Of Units For $0.75 Million
Generex Biotech Completes Private Placement Of Units For $2 Million
Generex Completes Private Placement Of Common Stock For $3 Million
Generex Biotech Completes First Tranche Of Private Placement For $3 Million
Generex Biotech Completes First Tranche Of Private Placement Of $0.94 Million
Generex Completes Registered Direct Offering Of $12 Million
Generex Biotech Completes Registered Direct Offering For $5.65 Million
Generex Biotech Completes Registered Direct Offering Of $10 Million
Generex Biotech Completes Registered Direct Offering For $5 Million
Generex Completes Private Placement Of 8% Secured Convertible Notes For $21 Million
LIST OF FIGURES
Generex Biotechnology Corporation – Pipeline by Indication, 2013
Generex Biotechnology Corporation – Pipeline by Stage of Development, 2013
Generex Biotechnology Corporation – Monotherapy Products in Pipeline, 2013
Generex Biotechnology Corporation – Combination Treatment Modalities in Pipeline, 2013
Generex Biotechnology Corporation – Pipeline By Route of Administration, 2013
Generex Biotechnology Corporation - Pipeline Products By Mechanism of Action, 2013